Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Down 60.5% in July

Bone Biologics Corp. (NASDAQ:BBLG) saw a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 26,560 shares, a decline of 60.5% from the June 30th total of 67,279 shares. Based on an average daily volume of 70,934 shares, the short-interest ratio is presently 0.4 days. Currently, 1.6% of the company’s shares are sold short.

Bone Biologics Stock Performance

Shares of BBLG stock opened at $1.07 on Monday. The stock has a market capitalization of $1.94 million, a P/E ratio of -0.47 and a beta of 0.90. The company has a 50 day moving average price of $1.29 and a 200 day moving average price of $1.33. Bone Biologics has a fifty-two week low of $1.05 and a fifty-two week high of $4.13.

Bone Biologics (NASDAQ:BBLG) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). On average, research analysts forecast that Bone Biologics will post -1.17 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Trading of Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC lifted its stake in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the quarter. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. Institutional investors and hedge funds own 34.30% of the company’s stock.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.